New clinical trial results from Eli Lilly show Zepbound demonstrates superior weight loss outcomes compared to Wegovy. The SURMOUNT-5 trial revealed that 31% of Zepbound users lost at least 25% of their body weight, versus 16% for Wegovy users.

Key findings from the 72-week trial of 751 participants include:

• Average weight loss: 50 pounds with Zepbound vs. 33 pounds with Wegovy
• Significant weight loss achieved: 20% of Zepbound users vs. 14% of Wegovy users
• Participants were overweight or obese with at least one comorbidity
• No participants had diabetes

Understanding Weight Loss Medications:

• Zepbound and Mounjaro (tirzepatide) target both GIP and GLP-1 receptors
• Wegovy and Ozempic (semaglutide) target only GLP-1 receptors
• All medications require weekly injections
• Must be combined with healthy diet and regular exercise
• Long-term commitment is necessary for sustained results

Important Considerations:

• Weight regain likely occurs if medication is stopped
• Side effects may include nausea, constipation, and abdominal pain
• Insurance coverage and access remain challenging
• Studies show benefits beyond weight loss, including cardiovascular improvements
• Recent FDA approval allows Wegovy to list heart-related benefits

Expert physicians emphasize that these medications require lifestyle changes and long-term commitment. Success depends on:

• Maintaining a healthy diet
• Regular physical exercise
• Adequate sleep
• Stress management
• Understanding that treatment may be lifelong

Recent research shows additional benefits of these medications, including reduced sleep apnea events and potential improvements in rheumatoid arthritis symptoms. The choice between medications should consider individual factors, insurance coverage, and potential side effects.

Related Articles

Previous Articles